BW

#CancelHate movement: PureSquare and Life After Hate team up to combat online hate and promote a kinder world

BOSTON--(BUSINESS WIRE)--PureSquare, a leading cybersecurity platform, is partnering with nonprofit organization Life After Hate to combat hate speech through the #CancelHate initiative. For every tweet supporting the campaign, PureSquare has pledged to donate $1 to Life After Hate. The rise of hate speech and online harassment is a growing concern…
Leer más...

TGT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Target Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Target Corporation (NYSE: TGT) common stock between August 18, 2021 and May 17, 2022, both dates inclusive (the “Class Period”) have until May 30, 2023 to seek appointment as lead plaintiff in…
Leer más...

REDWIRE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Redwire Corporation – RDW

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Redwire Corporation (NYSE: RDW). In November 2021, the Company disclosed that it could not timely file its…
Leer más...

REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. – RETA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Reata Pharmaceuticals, Inc. (NasdaqGM: RETA). In December 2021, the U.S. Food and Drug Administration (“FDA”) released briefing…
Leer más...

ClearOne, Inc. Reports Fourth Quarter 2022 Financial Results

Records GAAP EPS of $0.83 after accounting for one-time legal settlement receivable of $55 million Delays in manufacturing transition contribute to revenue decrease even as unfulfilled orders keep growing Overall revenue decreases by 44% Non-GAAP Opex declines by 24% SALT LAKE CITY--(BUSINESS WIRE)--ClearOne (NASDAQ: CLRO), a global provider of audio…
Leer más...

TEST REPORTS

Core Net New Assets Rise 69% to a New All-Time High of $65.6 BillionSAN FRANCISCO--(BUSINESS WIRE)--April 16, 2018 – The Big Test Corporation announced today that its net income for the first quarter of 2018 was a record $783 million, up 31% from $597 million for the prior quarter, and…
Leer más...

TGT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Target Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Target Corporation (NYSE: TGT) common stock between August 18, 2021 and May 17, 2022, both dates inclusive (the “Class Period”) have until May 30, 2023 to seek appointment as lead plaintiff in…
Leer más...

REDWIRE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Redwire Corporation – RDW

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Redwire Corporation (NYSE: RDW). In November 2021, the Company disclosed that it could not timely file its…
Leer más...

REATA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. – RETA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Reata Pharmaceuticals, Inc. (NasdaqGM: RETA). In December 2021, the U.S. Food and Drug Administration (“FDA”) released briefing…
Leer más...